Academic Journals Database
Disseminating quality controlled scientific knowledge

Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis

Author(s): Gabriel L Reep | Roger D Soloway

Journal: World Journal of Hepatology
ISSN 1948-5182

Volume: 3;
Issue: 8;
Start page: 211;
Date: 2011;
Original page

Keywords: Alcoholic hepatitis | Tumor necrosis factor-α inhibitors | Infliximab | Etanercept | Antioxidants | Probiotics | Rifaximin | Betaine | Granulocytapheresis

Patients with severe alcoholic hepatitis (AH) need to be treated with specific treatment for better outcome. Currently available specific treatment modalities are use of corticosteroids or pentoxifylline. However, the response rate to these drugs is only about 50%-60%. Hence, there is an urgent need for better and more effective treatment options. Tumor necrosis factor plays an important role in the pathogenesis of AH. However, agents blocking the action of tumor necrosis factor have not been found to be effective. Rather the randomized studies evaluating these agents showed an adverse effect and more infections in treated patients. Critical role of tumor necrosis factor in hepatic regeneration explaining this contrast is discussed. Oxidative stress and inflammation derived from gut bacteria ate two main components in the pathogenesis of AH laying foundation for the role of antioxidants, probiotics, and antibiotics in the management of AH. This article reviews the current data and status of these newer agents for the treatment of AH. Of the various options available, Vitamin E and N-acetylcysteine (NAC) have shown great promise for clinical use as adjunct to corticosteroids. With these encouraging data, future well designed studies are suggested to assess Vitamin E and NAC before their routine use in clinical practice in the management of AH.

Tango Jona
Tangokurs Rapperswil-Jona

     Save time & money - Smart Internet Solutions